Prostate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase
LOS ANGELES — The Prostate Cancer Foundation (PCF) announced on October 17 the expansion of its Radiopharmaceutical Think Tank, adding new members and establishing its 2026-2027 agenda focused on accelerating development and patient access of novel radiopharmaceutical drugs for cancer treatment. PCF announced the second-year Think Tank program in conjunction with the European Association of Nuclear Medicine (EANM) Annual Congress, taking place October 17-21 in Vienna, Austria.
New Think Tank members for the 2026-2027 term include Orano Med, Telix Pharmaceuticals and Siemens Healthineers. They join existing members Actithera, Advancell, Artbio, AstraZeneca, Bayer, Bicycle Therapeutics, Clarity Pharmaceuticals, Curium and Novartis. Beginning with its kickoff meeting at the EANM Annual Congress this month, the Think Tank will convene four times during its new term.
PCF established the Radiopharmaceutical Think Tank in October 2025 to bring together senior leaders from industry, medicine and other disciplines. In its second year, the Think Tank will focus on identifying and prioritizing barriers to radiopharmaceutical development and access, bringing those issues to broader oncology, regulatory and payer communities, working toward potential solutions, and applying lessons from prostate cancer to radiopharmaceutical development across a variety of tumor types.
"The science around radiopharmaceuticals is moving quickly, and the systems needed to develop and deliver these therapies have to keep pace to optimize their benefits for patients across a broad range of cancers," said Oliver Sartor, M.D., Director of the Translational Oncology Research Program at Tulane University School of Medicine and Chair of the Radiopharmaceutical Think Tank. Phillip J. Koo, M.D., PCF's Executive Vice President and Chief Medical Officer, said radiopharmaceuticals are creating important new opportunities in prostate cancer treatment, and that realizing their full potential for patients with other cancers requires expertise and coordination from many different areas.
According to PCF, radiopharmaceuticals have moved beyond their traditional role in specialized diagnostics to become an increasingly important therapeutic approach in cancer care, with PSMA-targeted radioligand therapy helping establish the clinical and commercial potential of the approach in prostate cancer, while development continues across earlier stages of disease and other tumor types. Founded in 1993 by Mike Milken, PCF has raised more than $1.2 billion to fund more than 2,615 research projects at 312 leading cancer centers, with a global footprint spanning 29 countries.
Published by GSM · USA (original Chinese edition)
Photo: 资料图：前列腺癌PSMA PET/CT影像（Rauscher等，《Cancer Imaging》2016，CC BY 4.0，via Wikimedia Commons）
